PPA-containing medicines ban having little impact to six Korea drug makers in Korea Stock Exchange
Overall, the share prices of six pharmaceutical firms producing phenylpropanolamine (PPA) based cold remedies showed little sign of plunge between July 30 to August 5, despite the recent jitters over PPA drugs ban.
Though a correction is expected, this in itself will not likely become ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
